165 related articles for article (PubMed ID: 3402470)
21. One year experience in the treatment of familial hypercholesterolaemia with simvastatin.
Quiney J; Watts GF; Kerr-Muir M; Slavin B; Lewis B
Postgrad Med J; 1992 Jul; 68(801):575-80. PubMed ID: 1437957
[TBL] [Abstract][Full Text] [Related]
22. Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158-->Cys), E3-Leiden, and E2(Lys146-->Gln), and effects of treatment with simvastatin.
Zhao SP; Smelt AH; Van den Maagdenberg AM; Van Tol A; Vroom TF; Gevers Leuven JA; Frants RR; Havekes LM; Van der Laarse A; Van 't Hooft FM
Arterioscler Thromb; 1994 Nov; 14(11):1705-16. PubMed ID: 7947593
[TBL] [Abstract][Full Text] [Related]
23. [Swiss simvastatin multicenter study: 1. Efficacy of 10 mg simvastatin daily in patients with primary hypercholesterolemia].
Riesen WF; Keller U; Del Bufalo A; Reutter FW; Baur HR; Golay A; Bertel O; Kummer H; Kistler H; Ammann F
Schweiz Med Wochenschr; 1989 Dec; 119(48):1719-23. PubMed ID: 2694363
[TBL] [Abstract][Full Text] [Related]
24. [Effectiveness, tolerance and safety of simvastatin in comparison with bezafibrate in treatment of hypercholesterolemia].
Lechleitner M; Sailer S; Irsigler H; Klein W; Patsch JR
Wien Med Wochenschr; 1995; 145(21):577-83. PubMed ID: 8560901
[TBL] [Abstract][Full Text] [Related]
25. [Effects of simvastatin on plasma lipoproteins].
Alessandri C; Basili S; Maurelli M; Andreozzi P; Bracaglia D; Cordova C
Clin Ter; 1994 Jan; 144(1):3-9. PubMed ID: 8168349
[TBL] [Abstract][Full Text] [Related]
26. Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures.
Farrer M; Winocour PH; Evans K; Neil HA; Laker MF; Kesteven P; Alberti KG
Diabetes Res Clin Pract; 1994 Mar; 23(2):111-9. PubMed ID: 8070302
[TBL] [Abstract][Full Text] [Related]
27. The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis.
Bach LA; Cooper ME; O'Brien RC; Jerums G
J Am Geriatr Soc; 1990 Jan; 38(1):10-4. PubMed ID: 2404052
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia.
Frohlich J; Brun LD; Blank D; Campeau L; Crockford P; Curnew G; Dafoe W; Davignon J; Dufour R; Emery G
Can J Cardiol; 1993 Jun; 9(5):405-12. PubMed ID: 8348392
[TBL] [Abstract][Full Text] [Related]
29. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy.
Hommel E; Andersen P; Gall MA; Nielsen F; Jensen B; Rossing P; Dyerberg J; Parving HH
Diabetologia; 1992 May; 35(5):447-51. PubMed ID: 1521727
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. European Study Group.
Lambrecht LJ; Malini PL
Acta Cardiol; 1993; 48(6):541-54. PubMed ID: 8122478
[TBL] [Abstract][Full Text] [Related]
31. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
32. Simvastatin (MK 733): an effective treatment for hypercholesterolemia.
Lintott CJ; Scott RS; Nye ER; Robertson MC; Sutherland WH
Aust N Z J Med; 1989 Aug; 19(4):317-20. PubMed ID: 2675812
[TBL] [Abstract][Full Text] [Related]
33. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.
Mitropoulos KA; Armitage JM; Collins R; Meade TW; Reeves BE; Wallendszus KR; Wilson SS; Lawson A; Peto R
Eur Heart J; 1997 Feb; 18(2):235-41. PubMed ID: 9043839
[TBL] [Abstract][Full Text] [Related]
34. Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients.
Wanner C; Lubrich-Birkner I; Summ O; Wieland H; Schollmeyer P
Nephron; 1992; 62(1):40-6. PubMed ID: 1436290
[TBL] [Abstract][Full Text] [Related]
35. Bezafibrate and simvastatin (MK-733) in the treatment of primary hypercholesterolaemia.
Smith DH; Neutel JM; Jankelow D; Myburgh DP
S Afr Med J; 1990 May; 77(10):500-3. PubMed ID: 2188379
[TBL] [Abstract][Full Text] [Related]
36. Simvastatin in non-insulin-dependent diabetic patients with hypercholesterolaemia.
Steyn K; Weich HF; Bonnici F; Kotze TJ; Stander I; Vermaak WJ; Lourens W; van Lathem J; Omar MA; Fourie J
S Afr Med J; 1992 Dec; 82(6):402-6. PubMed ID: 1465688
[TBL] [Abstract][Full Text] [Related]
37. Simvastatin in the effective reduction of plasma lipoprotein levels in familial dysbetalipoproteinemia (type III hyperlipoproteinemia).
Stuyt PM; Mol MJ; Stalenhoef AF; Demacker PN; Van 't Laar A
Am J Med; 1990 Jan; 88(1N):42N-45N. PubMed ID: 2368763
[TBL] [Abstract][Full Text] [Related]
38. Decreased mitogenic activity in hypercholesterolaemic plasma.
Mölgaard J; Carlsson M; Nilsson J; Olsson AG
J Intern Med; 1990 May; 227(5):339-45. PubMed ID: 2341827
[TBL] [Abstract][Full Text] [Related]
39. A one-year multicentre study of simvastatin in the treatment of hypercholesterolaemia. UK and Eire Simvastatin Study Group.
Br J Clin Pract; 1994; 48(5):231-5. PubMed ID: 7917813
[TBL] [Abstract][Full Text] [Related]
40. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition.
Bard JM; Parra HJ; Camare R; Luc G; Ziegler O; Dachet C; Bruckert E; Douste-Blazy P; Drouin P; Jacotot B
Metabolism; 1992 May; 41(5):498-503. PubMed ID: 1588829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
